MedTrace Logo

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid

NCT07210554 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-10-07

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.

Conditions

  • Bullous Pemphigoid (BP)

Interventions

BIOLOGICAL

Stapokibart injection

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Sponsors & Collaborators

  • Chengdu Kangnuoxing Biopharma,Inc.

    lead INDUSTRY

Principal Investigators

  • Hang Li, Chief physician · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-11
Primary Completion
2028-03-27
Completion
2028-05-08

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07210554 on ClinicalTrials.gov